Bio-Path Holdings Inc
BPTH Real Time Price USDRecent trades of BPTH by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BPTH's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Sep. 24, 2024
-
Patent Title: Combination therapy with liposomal antisense oligonucleotides Jun. 18, 2024
-
Patent Title: P-ethoxy nucleic acids for stat3 inhibition Jun. 22, 2021
-
Patent Title: Combination therapy with liposomal antisense oligonucleotides Feb. 23, 2021
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Jan. 26, 2021
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Jul. 02, 2019
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Aug. 29, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of BPTH in WallStreetBets Daily Discussion
Recent insights relating to BPTH
Recent picks made for BPTH stock on CNBC
ETFs with the largest estimated holdings in BPTH
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BPTH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.